Tepotinib in Sorafenib-Pretreated Patients With Advanced HCC With MET Overexpression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1b/2 Trial of Tepotinib in Sorafenib Pretreated Advanced Hepatocellular Carcinoma With MET Overexpression
Br. J. Cancer 2021 Apr 06;[EPub Ahead of Print], T Decaens, C Barone, E Assenat, M Wermke, A Fasolo, P Merle, JF Blanc, V Grando, A Iacobellis, E Villa, J Trojan, J Straub, R Bruns, K Berghoff, J Scheele, E Raymond, S FaivreFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.